Aytu BioPharma, Inc. (AYTU)
NASDAQ: AYTU · Real-Time Price · USD
2.260
+0.080 (3.67%)
At close: Jul 1, 2025, 4:00 PM
2.260
0.00 (0.00%)
After-hours: Jul 1, 2025, 4:04 PM EDT
Aytu BioPharma Employees
Aytu BioPharma had 102 employees as of June 30, 2024. The number of employees decreased by 48 or -32.00% compared to the previous year.
Employees
102
Change (1Y)
-48
Growth (1Y)
-32.00%
Revenue / Employee
$800,578
Profits / Employee
$16,069
Market Cap
20.29M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AYTU News
- 6 days ago - Aytu BioPharma Appoints Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs to Support Commercialization of EXXUA(TM) - Accesswire
- 8 days ago - Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA(TM) - Accesswire
- 22 days ago - Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA(TM) Opportunity and Commercialization Plan - Accesswire
- 25 days ago - Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock - Accesswire
- 25 days ago - Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA(TM) (gepirone) Extended-Release Tablets in the United States - Accesswire
- 6 weeks ago - Aytu BioPharma, Inc. (Aytu ) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results - Accesswire
- 7 weeks ago - Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025 - Accesswire